Nasus Pharma LtdNSRX

Nasus Pharma Ltd. spent 2025 losing money faster than most people lose umbrellas in London buses. The company reported revenues of $1.24 billion-yes, with a ‘b’-but its net income attributable to shareholders clocked in at minus $5.9 million, a loss so polite it even filed on time with the SEC in its 20-F for the year ended December 31, 2025. Operating income was also in negative territory at minus $4.9 million, a figure that would make accountants flinch if it weren’t for the fact that the company’s entire asset base was only $5.0 million, of which just $1.2 million was cash. That’s a working capital situation so tight it reads like a joke the company hopes no one finishes. (source: 20-F (2025-12-31), Nasus Pharma Ltd., https://www.sec.gov/Archives/edgar/data/2029039/000149315226018607/xslF345X06/ownership.xml)

Nasus’s pipeline is anchored on intranasal ondansetron (NS003), a formulation that aims to replace tablets or injections with a quick nasal puff for chemotherapy-induced nausea. The company’s June 9, 2026 6-K includes a press release titled ‘Nasus Pharma Announces Positive Results from Preclinical Pharmacokinetic and Safety Study of Intranasal Ondansetron (NS003)’ and even attaches it as Exhibit 99.1, proving that in biotech, the filing trail can be as critical as the placebo. The filing, however, does not disclose sample size, adverse events, or whether test subjects preferred the spray over a paper bag. What it does show is that the company is still in the early innings of proving that NS003 can do what its name suggests: soothe a patient without soaking a couch. (source: NSRX 6-K (2026-06-09), Nasus Pharma Ltd., https://www.sec.gov/Archives/edgar/data/2029039/000149315226027929/form6-k.htm)

The balance sheet numbers are not for the faint of heart. At year-end 2025, Nasus’s stockholders’ equity was $2.8 million, comfortably outgunned by its liabilities of $2.2 million. Cash and equivalents stood at $1.2 million, while operating cash burn was minus $4.9 million, a cash-flow haemorrhage that would make a haemophiliac reach for a stronger anticoagulant. Research and development spend was $2.2 million, a figure that dwarfs the $14,000 spent on property, plant, and equipment-roughly the cost of a single MRI machine’s service contract. Earnings per share, diluted, were minus $0.72 on 8.0 million shares, which is either a bargain price for a front-row seat to science or a polite invitation to question why the company hasn’t yet monetised the view. (source: 20-F (2025-12-31), Nasus Pharma Ltd., https://www.sec.gov/Archives/edgar/data/2029039/000149315226018607/xslF345X06/ownership.xml)

For those tracking the stock, the most recent ownership filings show steady institutional presence. A May 15, 2026 Schedule 13G indicates a passive holder with no intention to influence management, while earlier April and June filings chart the same passive posture-hardly the stuff of activist campaigns, but perhaps a relief to a board already juggling chemistry, cash, and credibility. The company’s SEC index lists dozens of filings, but the only items that move the needle are the financials, the 6-K with the NS003 press release, and routine officer appointments such as the May 26 S-8 that named Dan Teleman and Eyal Rubin to the board. (source: Schedule 13G (2026-05-15), S-8 (2026-05-26), Nasus Pharma Ltd., https://www.sec.gov/Archives/edgar/data/2029039/000207367926000045/xslSCHEDULE_13G_X02/primary_doc.xml; https://www.sec.gov/Archives/edgar/data/2029039/000149315226025278/forms-8.htm)

What hasn’t changed is the company’s dependence on external financing to keep NS003’s preclinical engine running. With less than $1.2 million in cash at year-end 2025 and operating cash burn of $4.9 million, the runway is measured in weeks rather than years. The positive preclinical results for NS003 are welcome, but preclinical is to medicine what a first draft is to a novel: promising, early, and still prone to plot twists. The company has not disclosed timelines for human trials, regulatory pathways, or manufacturing scale-up, leaving investors to decide whether to bet on a nasal spray or a mirage. (source: 20-F (2025-12-31), 6-K (2026-06-09), Nasus Pharma Ltd., https://www.sec.gov/Archives/edgar/data/2029039/000149315226018607/xslF345X06/ownership.xml; https://www.sec.gov/Archives/edgar/data/2029039/000149315226027929/form6-k.htm)

For now, the Nasus story is less about blockbuster approvals and more about block-and-tackle financing. The company’s SEC filings read like a masterclass in how to file a lot of paper while running low on cash. There is no schedule for the next equity raise, no guidance on cash needs, and no sign that the intranasal spray will reach a patient before the next rent payment falls due. Until then, Nasus Pharma remains a company whose headline numbers are bigger than its bank balance, and whose science is bigger than its shareholder equity. (source: 20-F (2025-12-31), SEC filings index, Nasus Pharma Ltd., https://www.sec.gov/edgar/browse/?CIK=2029039; https://www.sec.gov/Archives/edgar/data/2029039/000149315226018607/xslF345X06/ownership.xml)